Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Bioequivalence of DMB-3113 vs Adalimumab in Healthy Japanese Males
NCT02927353Phase 1Completed
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Aug 2016
- Primary completion
- Jan 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoints: Area under the serum concentration-time curve from 0 to final sampling time point, Area under the serum concentration-time curve from 0 to infinity and 1 more. Started Aug 2016; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02927353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02927353.